KBC Securities - MAAT PHARMA SA (MAAT) Morning Notes : MAAT FP

Report

KBC Securities

Hilde Van Boxstael ...

Jacob Mekhael
Wim Lewi

Morning Notes : MAAT FP

: MAAT FP

12/05/2025 1 EN

Underlying

MAAT PHARMA SA

See profile

FR0012634822 Euronext Paris France

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Hilde Van Boxstael

Jacob Mekhael

Wim Lewi

Other Reports on these Companies

KBC Securities

MaaT Pharma FIRST LOOK: MaaT033 slows disease progression in phase 1 ALS trial

MaaT reported additional results from the exploratory single arm phase 1b trial of MaaT033 in ALS, and we view the slower disease progression observed with MaaT033 as encouraging, though we also note the small patient numbers and single arm nature of the trial. ALS is a difficult condition, where many drugs have failed to show slowing of disease progression. As such, MaaT033's early results are promising, and the company is seeking partners focussed on ALS to progress this program. We reiterate our € 17 TP and Buy rating.

7h / 16m 7h / 16m 1 EN

KBC Securities

Morning Notes : IMMO BB, RECT BB, EKOP BB, MAAT FP

: IMMO BB, RECT BB, EKOP BB, MAAT FP

April 29, 2025 April 29, 2025 1 EN

Tessenderlo FIRST LOOK: Creating a global leader in gelatin/collagen with Darling Ingr.

Tessenderlo and Darling Ingredients announced the intention to combine their gelatin & collagen businesses in a joint venture, in which Tessenderlo would have a 15% stake. In light of the difficult market conditions, we welcome the combination which will lead to a gelatin & collagen powerhouse with a global market share of 35-40%. We still appreciate Tessenderlo for the sizeable free cash flow generation and maintain our Accumulate rating for now.

5h / 39m 5h / 39m 1 EN

Jacob Mekhael

Jacob Mekhael

MaaT Pharma FIRST LOOK: MaaT033 slows disease progression in phase 1 ALS trial

7h / 16m 7h / 16m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Morning Notes : MAAT FP

We are a financial services provider for several types of professional clients, each with distinct needs.

MaaT Pharma FIRST LOOK: MaaT033 slows disease progression in phase 1 ALS trial

Morning Notes : IMMO BB, RECT BB, EKOP BB, MAAT FP

Tessenderlo FIRST LOOK: Creating a global leader in gelatin/collagen with Darling Ingr.

MaaT Pharma FIRST LOOK: MaaT033 slows disease progression in phase 1 ALS trial

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe